Revance Therapeutics, Inc. Common Stock Underwriting Agreement January 16, 2019Underwriting Agreement • January 17th, 2019 • Revance Therapeutics, Inc. • Pharmaceutical preparations • New York
Revance Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 5,882,353 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 882,352 additional shares (the “Optional Shares”) of common stock, $0.001 par value per share (“Stock”) of the Company. The Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof are herein collectively called the “Securities”.
